C4 THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.8 USD | +5.43% |
|
+5.75% | +20.35% |
| May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
| May. 08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 27.24M | Sales 2025 * | 24.78M | Capitalization | 468M |
|---|---|---|---|---|---|
| Net income 2024 * | -123M | Net income 2025 * | -149M | EV / Sales 2024 * | 3.44 x |
| Net cash position 2024 * | 374M | Net cash position 2025 * | 325M | EV / Sales 2025 * | 5.76 x |
| P/E ratio 2024 * |
-4.11
x | P/E ratio 2025 * |
-3.6
x | Employees | 145 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on C4 Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +5.43% | ||
| 1 week | +5.75% | ||
| Current month | +7.94% | ||
| 1 month | -14.68% | ||
| 3 months | +10.57% | ||
| 6 months | +286.36% | ||
| Current year | +20.35% |
1 week
6.36
7.29
1 month
6.128.08
Current year
5.0011.88
1 year
1.0611.88
3 years
1.0651.21
5 years
1.0651.21
10 years
1.0651.21
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Hirsch
CEO | Chief Executive Officer | 53 | 20-09-13 |
Kendra Adams
DFI | Director of Finance/CFO | 48 | 20-11-19 |
| Chief Tech/Sci/R&D Officer | - | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bruce Downey
CHM | Chairman | 76 | 15-11-30 |
Glenn Dubin
BRD | Director/Board Member | 67 | 21-03-11 |
Bihua Chen
PRN | Corporate Officer/Principal | 55 | 15-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 6.8 | +5.43% | 1,644,649 |
| 24-05-08 | 6.45 | -5.01% | 2,397,099 |
| 24-05-07 | 6.79 | +1.19% | 888,340 |
| 24-05-06 | 6.71 | -0.45% | 1,182,769 |
| 24-05-03 | 6.74 | +4.82% | 941,632 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patientsâ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the bodyâs natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.8
USD
Average target price
17.22
USD
Spread / Average Target
+153.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.35% | 468M | |
| +23.37% | 47.02B | |
| +49.51% | 41.86B | |
| -0.94% | 41.76B | |
| -5.86% | 28.8B | |
| +11.29% | 26.05B | |
| -20.92% | 19.15B | |
| +3.20% | 12.55B | |
| -2.67% | 11.82B | |
| +30.23% | 12.34B |
- Stock Market
- Equities
- CCCC Stock